3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
42
Specimen Handling
38
Magnetic Resonance Spectroscopy
30
Carboplatin
30
Cyclophosphamide
27
Biopsy
25
Nivolumab
23
Dexamethasone
22
fludarabine
21
Gemcitabine
19
Bevacizumab
15
Paclitaxel
14
Temozolomide
13
Pemetrexed
13
Docetaxel
13
Cisplatin
13
atezolizumab
12
Ipilimumab
12
Rituximab
11
venetoclax
10
Prednisone
10
Lenalidomide
9
Injections
9
Fulvestrant
9
lenvatinib
8
X-Rays
8
Vincristine
8
Trastuzumab
8
Oxaliplatin
8
Fluorouracil
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Histamine H2 Antagonists
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled